If you need help accessing our website, call 855-698-9991
Theresa Ryan at [NYU Langone Health]
NYU Langone Provider

Theresa Ryan, MD

NYU Langone Provider
  • Specialty: Medical Oncology
  • Treats: Adults
  • Language: English

Conditions and Treatments

Conditions
  • abdominal tumor
  • anal cancer
  • bile duct cancer
  • biliary cancer
  • cancer
  • carcinoid tumor
  • colon cancer
  • colorectal cancer
  • esophageal cancer
  • gallbladder cancer
  • gastrointestinal neuroendocrine tumor
  • hereditary nonpolyposis colorectal cancer
  • liver cancer
  • liver cell cancer
  • pancreatic cancer
  • rectal cancer
  • stomach cancer
Treatments
  • bloodless medicine
  • gastrointestinal surgery

Positions
Board Certifications
  • American Board of Preventive Medicine (Clinical Informatics), 2022
  • American Board of Internal Medicine (Medical Oncology), 2003
Education and Training
  • Fellowship, New York University School of Medicine, Hematology Oncology, 2003
  • Residency, New York University School of Medicine, Medicine, 2000
  • MD from New York University, 1996

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Theresa Ryan, MD does not accept insurance.

  • A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

    Learn More
  • A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

    Learn More
  • EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence

    Learn More
View All Research Studies (6)

Read All Publications (25)